COLUMN A COLUMN B Agenerase
Retrovir plus Hivid Fortovase Videx plus Epivir Norvir Rescriptor Viracept plus Fortovase Viramune Ziagen
TABLE: Currently approved medications for treating HIV/AIDS Protease Entry Nukes Non-nukes Inhibitors Inhibitors Combivir Rescriptor Agenerase
Fuzeon (Epivir + Retrovir) Emtriva Sustiva Crixivan Epivir Viramune Fortovase Hivid Invirase Retrovir Kaletra Trizivir (Epivir + Lexiva Retrovir + Ziagen) Videx (regular or EC) Norvir Viread Reyataz Zerit Viracept Ziagen
On February 5, 2002, FDA approved a new dosing regimen for Agenerase
(amprenavir) and Norvir (ritonavir) used in combination.
The reason this drug is important is that the current version of Agenerase
requires taking 16 large capsules a day.
purchased, the Company's right to receive future royalty payments, net of sub-royalty payments due to a third party, arising from sales of Lexiva/Telzir and Agenerase
under the Company's 1993 license agreement with GlaxoSmithKline plc for periods commencing April 1, 2008, in return for a one-time cash payment of $160.
First, taking Agenerase
and Methadone is not recommended because Agenerase
lowers the levels of Methadone in the blood, and Agenerase
may not be absorbed as well when taken with Methadone.
0 million for sale of the Company's rights to future royalties of the HIV protease inhibitors Lexiva/Telzir and Agenerase
under the Company's 1993 license agreement with GlaxoSmithKline plc.
2003, has shown to be similar in efficacy to AGENERASE
, but offers a number of dosing benefits over AGENERASE
The study was done to see if the combination of the two drugs would help reduce the number of Agenerase
pills required per day (16 large pills).
As a result of the sale of the future royalties, Vertex will no longer make royalty payments to the third party with respect to Lexiva and Agenerase
When the two are used in combination, 1200 mg of Agenerase
can be given with 200 mg of Norvir once a day, or 600 mg of Agenerase
can be given with 100 mg of Norvir twice a day.
The drug, sold by GlaxoSmithKline (NYSE: GSK), has a convenient dosing and favorable metabolic profile relative to first-generation protease inhibitors such as Agenerase
, Crixivan, and Viracept.